ABSK121 / Abbisko - LARVOL DELTA

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=169 | Recruiting | Sponsor: Abbisko Therapeutics Co, Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2022 ➔ Jun 2023

Enrollment open • Metastases • Trial initiation date • Cholangiocarcinoma • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • FGFR2

Discovery and characterization of a next-generation FGFR inhibitor overcoming FGFR resistant mutations (AACR 2023) - "Four selective FGFR inhibitors have been approved (erdafitinib, pemigatinib, infigratinib, and futibatinib) and several others are in clinical development. ABSK121, presented here by Abbisko Therapeutics, is a highly potent, selective, and next-generation small molecule FGFR inhibitor with great potency against resistant FGFR mutations. Its superior profile supports fast-track preclinical and clinical development."

Late-breaking abstract • Oncology • FGFR2

Abbisko presents the research results of 5 programs at the 2023 AACR Annual Meeting (PRNewswire) - "Abbisko...announced the results of five latest preclinical studies at the 2023 American Association for Cancer Research (AACR) annual meeting....Abstract Number: LB317:...ABSK121, presented here by Abbisko Therapeutics, is a highly potent, selective, and next-generation small molecule FGFR inhibitor with great potency against resistant FGFR mutations. Its superior profile supports fast-track preclinical and clinical development."

Preclinical • Oncology • Solid Tumor • FGFR

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=169 | Not yet recruiting | Sponsor: Abbisko Therapeutics Co, Ltd

New P1 trial • Cholangiocarcinoma • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • FGFR2